RxSight, Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
RXST$4.90+0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating Activities: | ||
| Net loss | $(8,190) | $(9,100) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 776 | 1,115 |
| Provision for bad debts | 21 | — |
| Amortization of right-of-use lease assets | 9 | 25 |
| Amortization of discount on short-term investments | (2,411) | (1,505) |
| Stock-based compensation | 7,140 | 4,696 |
| Provision for excess and obsolete inventory | 31 | 111 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (928) | (1,269) |
| Inventories | (1,597) | (1,390) |
| Prepaid and other assets | 254 | 569 |
| Accounts payable | 2,226 | 1,176 |
| Accrued expenses and other liabilities | (6,163) | (3,737) |
| Net cash used in operating activities | (8,832) | (9,309) |
| Investing Activities: | ||
| Purchases of property and equipment | (575) | (1,967) |
| Maturities of short-term investments | 60,000 | 74,000 |
| Purchases of short-term investments | (38,570) | (47,759) |
| Net cash provided by investing activities | 20,855 | 24,274 |
| Financing Activities: | ||
| Proceeds from issuance of common stock | 696 | 10,153 |
| Payments for employee taxes related to stock compensation | (1,418) | (2,134) |
| Principal payments on finance lease liabilities | (13) | (27) |
| Net cash (used in) provided by financing activities | (735) | 7,992 |
| Effect of foreign exchange rate on cash, cash equivalents and restricted cash | 6 | (3) |
| Net increase in cash, cash equivalents and restricted cash | 11,294 | 22,954 |
| Cash, cash equivalents and restricted cash - beginning of period | 17,456 | 10,402 |
| Cash, cash equivalents and restricted cash - end of period | $28,750 | $33,356 |
| Supplemental disclosure of cash flow information: | ||
| Operating cash flows from operating leases | 694 | 548 |
| Cash paid for income taxes | 3 | — |
| Cash paid for interest on financing leases | 5 | 5 |
| Non-cash investing and financing activities: | ||
| Acquisition of property and equipment included in accounts payable and accrued expenses and accrued liabilities | 204 | 343 |
| Deferred offering and financing costs included in accounts payable and accrued liabilities | — | 225 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.